Liminal BioSciences Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was CAD 0.157 million compared to CAD 0.025 million a year ago. Net loss was CAD 5.94 million compared to CAD 32.04 million a year ago. Basic loss per share from continuing operations was CAD 2 compared to CAD 4.2 a year ago. Basic loss per share was CAD 1.9 compared to CAD 10.7 a year ago.
For the six months, sales was CAD 0.157 million compared to CAD 0.235 million a year ago. Net loss was CAD 16.54 million compared to CAD 52.31 million a year ago. Basic loss per share from continuing operations was CAD 5.5 compared to CAD 8.7 a year ago. Basic loss per share was CAD 5.3 compared to CAD 17.5 a year ago.